Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
103 GBX | +1.58% | +4.04% | +19.91% |
Mar. 27 | Sainsbury's, Petershill Partners upped to 'buy' | AN |
Mar. 18 | Exane raises Rentokil; RBC cuts Centrica | AN |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 51% by 2026.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company sustains low margins.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+19.91% | 1.33B | C+ | ||
+6.49% | 50.92B | B+ | ||
+1.35% | 48.11B | B | ||
+9.53% | 42.2B | B+ | ||
+6.55% | 39.71B | B+ | ||
+19.34% | 37.78B | B | ||
+2.84% | 30.07B | B | ||
-7.77% | 27.56B | B- | ||
-18.42% | 24.71B | A- | ||
+6.89% | 21.99B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JRP Stock
- Ratings Just Group plc